All In Biotech

Drug Trial Radar · NCT02706873

A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate

A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects With Moderately to Severely Active Rheumatoid Arthritis

Last checked: Nov 19, 2026Latest source record: Jul 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,002 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,002

Actual

Start

Feb 23, 2016

Primary completion

Mar 15, 2018

Study completion Nov 10, 2022

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Mar 11, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of Period 1 were the following: * To compare the safety and efficacy of upadacitinib 7.5 mg once daily (QD) monotherapy (for participants in Japan only), 15 mg QD monotherapy, and 30 mg QD monotherapy versus weekly methotrexate monotherapy for the treatment of signs and symptoms of RA in methotrexate-naïve adults with moderately to severely active RA; * To compare the efficacy of upadacitinib 15 mg QD monotherapy and upadacitinib 30 mg QD monotherapy versus weekly methotrexate monotherapy for prevention of structural progression in methotrexate-naïve adults with moderately to severely active RA. The objective of Period 2 is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 7.5 mg QD (for participants in Japan only), 15 mg QD, and 30 mg QD in adults with RA who have completed Period 1.

Conditions

  • Rheumatoid Arthritis

Interventions

  • Placebo to UpadacitinibDrug

    Tablet; Oral

  • MethotrexateDrug

    Capsule or Tablet; Oral

  • Placebo to MethotrexateDrug

    Capsule or Tablet; Oral

  • UpadacitinibDrug

    Tablet; Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 - Global AnalysisTime frame: Baseline and Week 12
  2. Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 24 - Global AnalysisTime frame: Week 24
  3. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 - Global AnalysisTime frame: Baseline and Week 12
  4. Change From Baseline in Modified Total Sharp Score (mTSS) at Week 24 - Global AnalysisTime frame: Baseline to Week 24

Locations

290 sites in 45 countries. Site status is shown where the registry gives one.

  • TriWest Research Associates- La Mesa /ID# 143738

    La Mesa, California

  • Desert Medical Advances /ID# 143730

    Palm Desert, California

  • International Medical Research - Daytona /ID# 143748

    Daytona Beach, Florida

  • FL Med Ctr and Research, Inc. /ID# 143724

    Miami, Florida

  • Millennium Research /ID# 143736

    Ormond Beach, Florida

  • Arthritis Research of Florida /ID# 143743

    Palm Harbor, Florida

  • Sarasota Arthritis Center /ID# 145978

    Sarasota, Florida

  • FL Med Clinic, PA /ID# 143744

    Zephyrhills, Florida

  • Deerbrook Medical Associates /ID# 143728

    Vernon Hills, Illinois

  • Four Rivers Clinical Research /ID# 143741

    Paducah, Kentucky

  • Ocean Rheumatology, PA /ID# 143737

    Toms River, New Jersey

  • Arthritis Rheumatic Back Disorder /ID# 143733

    Voorhees Township, New Jersey

  • Trinity Health Med Arts Clinic /ID# 143727

    Minot, North Dakota

  • STAT Research, Inc. /ID# 143750

    Vandalia, Ohio

  • Healthcare Research Consultant /ID# 143747

    Tulsa, Oklahoma

  • Advanced Rheumatology & Arthri /ID# 147947

    Wexford, Pennsylvania

  • Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology /ID# 145653

    Summerville, South Carolina

  • West Tennessee Research Inst /ID# 143723

    Jackson, Tennessee

  • Dr. Ramesh Gupta /ID# 143732

    Memphis, Tennessee

  • Diagnostic Group Integrated He /ID# 152921

    Beaumont, Texas

  • Adriana Pop-Moody MD Clinic PA /ID# 147626

    Corpus Christi, Texas

  • Doctor's Hosp at Renaissance /ID# 156407

    Edinburg, Texas

  • MedResearch Inc. /ID# 156409

    El Paso, Texas

  • Rheumatic Disease Clin Res Ctr /ID# 151103

    Houston, Texas

  • Accurate Clinical Research /ID# 143749

    Houston, Texas

  • SW Rheumatology Res. LLC /ID# 143745

    Mesquite, Texas

  • Sun Research Institute /ID# 159546

    San Antonio, Texas

  • Accurate Clinical Management /ID# 159543

    San Antonio, Texas

  • NextGen Clinical Trials LLP /ID# 150930

    San Antonio, Texas

  • Arthritis Clinic of Central TX /ID# 159541

    San Marcos, Texas

  • Arthritis & Osteoporosis Clinic /ID# 159542

    Waco, Texas

  • Arthritis Clinic of N. VA, P.C /ID# 143734

    Arlington, Virginia

  • Org Medica de Investigacion /ID# 143142

    Buenos Aires, Argentina

  • Consultora Integral de Salud S /ID# 143144

    Córdoba, Argentina

  • Centro Integral de Reumatologi /ID# 143143

    San Miguel de Tucumán, Argentina

  • Centro Medico Privado/Reuma /ID# 143140

    San Miguel de Tucumán, Argentina

  • Aprillus Asistencia e Investig /ID# 149179

    Capital Federal, Buenos Aires, Argentina

  • Iari /Id# 148595

    San Isidro, Buenos Aires, Argentina

  • Instituto CAICI /ID# 143141

    Rosario, Santa Fe Province, Argentina

  • Royal Prince Alfred Hospital /ID# 143149

    Camperdown, New South Wales, Australia

Showing 40 of 290 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.